These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 28958385)

  • 1. Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.
    Fernández A
    Trends Cancer; 2017 Oct; 3(10):675-677. PubMed ID: 28958385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
    Lin AY; Lin E
    J Hematol Oncol; 2015 Nov; 8():124. PubMed ID: 26542241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
    Joshi SS; Maron SB; Catenacci DV
    Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.
    Mishima S; Taniguchi H; Akagi K; Baba E; Fujiwara Y; Hirasawa A; Ikeda M; Maeda O; Muro K; Nishihara H; Nishiyama H; Takano T; Tsuchihara K; Yatabe Y; Kodera Y; Yoshino T
    Int J Clin Oncol; 2020 Feb; 25(2):217-239. PubMed ID: 31286289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In brief: Pembrolizumab (Keytruda) for cancers with biomarkers.
    Med Lett Drugs Ther; 2018 Jan; 60(1537):e8. PubMed ID: 29294466
    [No Abstract]   [Full Text] [Related]  

  • 9. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.
    Cristescu R; Mogg R; Ayers M; Albright A; Murphy E; Yearley J; Sher X; Liu XQ; Lu H; Nebozhyn M; Zhang C; Lunceford JK; Joe A; Cheng J; Webber AL; Ibrahim N; Plimack ER; Ott PA; Seiwert TY; Ribas A; McClanahan TK; Tomassini JE; Loboda A; Kaufman D
    Science; 2018 Oct; 362(6411):. PubMed ID: 30309915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular classification and precision therapy of cancer: immune checkpoint inhibitors.
    Yu Y
    Front Med; 2018 Apr; 12(2):229-235. PubMed ID: 29209918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. When biomarkers define a drug indication.
    Jørgensen JT
    Expert Rev Mol Diagn; 2018 Apr; 18(4):315-317. PubMed ID: 29333885
    [No Abstract]   [Full Text] [Related]  

  • 12. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
    Lee V; Murphy A; Le DT; Diaz LA
    Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.
    Rousseau B; Foote MB; Maron SB; Diplas BH; Lu S; Argilés G; Cercek A; Diaz LA
    N Engl J Med; 2021 Mar; 384(12):1168-1170. PubMed ID: 33761214
    [No Abstract]   [Full Text] [Related]  

  • 17. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
    Colombo MP
    Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting Tumor Response to PD-1 Blockade.
    Ding L; Chen F
    N Engl J Med; 2019 Aug; 381(5):477-479. PubMed ID: 31365807
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.